How should Bevacizumab be administered intravenously?

Bevacizumab, a monoclonal antibody used in the treatment of various cancers, is administered intravenously primarily to ensure controlled delivery and reduce the risk of infusion-related reactions. It is essential to administer Bevacizumab through a method that permits careful observation of the patient, which is typically achieved through traditional IV infusion rather than a push method.

The infusion method allows for gradual circulation of the drug within the bloodstream, enabling closer monitoring for adverse effects and ensuring that high concentrations do not trigger severe reactions. Avoiding the push method, particularly a fast one, minimizes the risk of complications and contributes to better patient safety during the administration process. Thus, the recommendation to never administer Bevacizumab as a push aligns with best practices for chemotherapy and immunotherapy protocols.